Search

Your search keyword '"Perona, Monica"' showing total 41 results
Start Over Author "Perona, Monica"
41 results on '"Perona, Monica"'

1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author

Fiorinni, Giulia, Saracino, Ilaria Maria, Carrasco, Manuel Pabon, Huerga, Alma Keco, Almajano, Enrique Alfaro, Martinez Dominguez, Samuel Jesus, Galan, Horacio Alonso, Velayos, Benito, Sadornil, Carmen Dueñas, Botargues Bote, Jose Maria, Gonzalez-Cordero, Pedro Luis, Areia, Miguel, Gomez Rodriguez, Blas Jose, Pellicano, Rinaldo, Nuñez, Óscar, Franceschi, Francesco, Alekseenko, Sergey, Perona, Monica, Abdulkhakov, Rustam, Dominguez-Cajal, Manuel, Notari, Pedro Almela, Camarero, Judith Gomez, Moreno, Manuel Jimenez, Algaba, Alicia, Bermejo, Fernando, Tejada, Javier Tejedor, Susanibar, Elida Oblitas, Boltin, Doron, Georgopoulos, Sotirios, OMorain, Colm, Qasim, Asghar, Beales, Ian, Bakulina, Natalia, Fadeenko, Galina, Malfertheiner, Peter, Rosania, Rosa, Ilchishina, Tatiana, Bogomolov, Pavel, Bakulin, Igor, Zaytsev, Oleg, Gravina, Antonietta Gerarda, Romano, Marco, Di Leo, Alfredo, Losurdo, Giuseppe, Grigorieva, Ludmila, Guillena, Pedro Delgado, Marusic, Marinko, Jurcic, Dragan, Dekhnich, Natalia Nikolaevna, Iyo, Eduardo, de la Peña Negro, Luisa Carmen, Baryshnikova, Natalia, Bakanova, Natalia, Simsek, Halis, Simsek, Cem, Gridnyev, Oleksiy, Fernandez-Bermejo, Miguel, Angueira, Teresa, Ruiz-Zorrilla Lopez, Rafael, Gomez, Barbara, Kovacheva-Slavova, Mila, Lahat, Adi, Alcedo, Javier, Campillo, Ana, Belousova, Liya Nikolaevna, Villarroya, Ramon Pajares, Ljubicic, Neven, Nikolic, Marko, González-Santiago, Jesús M., Santamaría, Diego Burgos, Pakhomova, Anna, Sekulic-Spasic, Izabela, Ghisa, Matteo, Farinati, Fabio, Sagdati, Sabir Irfan, Panic, Nikola, Heluwaert, Frederic, Amorena, Edurne, Moreira, Leticia, Esparrach, Gloria Fernandez, Plotnikova, Ekaterina Yuryevna, Kukla, Michal, Kamburov, Victor, Lamuela Calvo, Luis Javier, Rankovic, Ivan, Lavín, Antonio Cuadrado, Lazaro, Yolanda Arguedas, Carrera Agnieszka Dobrowolska, Victor Gonzalez, Eder, Piotr, Kononova, Alla, Nyssen, Olga P., Vaira, Dino, Pérez Aísa, Ángeles, Rodrigo, Luis, Castro-Fernandez, Manuel, Jonaitis, Laimas, Tepes, Bojan, Vologzhanina, Liudmila, Caldas, María, Lanas, Angel, Lucendo, Alfredo J., Bujanda, Luis, Ortuño, Juan, Barrio, Jesús, Huguet, Jose M., Voynovan, Irina, Lasala, Jorge Perez, Sarsenbaeva, Aiman Silkanovna, Fernandez-Salazar, Luis, Molina-Infante, Javier, Jurecic, Natasa Brglez, Gasbarrini, Antonio, Kupčinskas, Juozas, Bordin, Dmitry, Marcos-Pinto, Ricardo, Lerang, Frode, Leja, Marcis, Buzas, Gyorgy M., Niv, Yaron, Rokkas, Theodore, Phull, Perminder, Smith, Sinead, Shvets, Oleg, Venerito, Marino, Milivojevic, Vladimir, Simsek, Ilkay, Lamy, Vincent, Bytzer, Peter, Boyanova, Lyudmila, Kunovský, Lumír, Beglinger, Christoph, Doulberis, Michael, Marlicz, Wojciech, Goldis, Adrian, Tonkić, Ante, Capelle, Lisette, Puig, Ignasi, Megraud, Francis, Morain, Colm O’, and Gisbert, Javier P.

Published
2022
Full Text
View/download PDF

3. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study

Author

Molina-Infante, Javier, Gutierrez-Junquera, Carolina, Savarino, Edoardo, Penagini, Roberto, Modolell, Ines, Bartolo, Ottavia, Prieto-García, Alicia, Mauro, Aurelio, Alcedo, Javier, Perelló, Antonia, Guarner-Argente, Carlos, Alcaide, Noelia, Vegas, Ana M., Barros-García, Patricia, Murzi-Pulgar, Marianette, Perona, Monica, Gisbert, Javier P., Lucendo, Alfredo J., and on behalf of the Upper GI Tract Study Group from the Spanish Gastroenterological Association (AEG)

Published
2018
Full Text
View/download PDF

4. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments

Author

Gisbert, Javier P., Romano, Marco, Molina-Infante, Javier, Lucendo, Alfredo J., Medina, Enrique, Modolell, Inés, Rodríguez-Tellez, Manuel, Gomez, Blas, Barrio, Jesús, Perona, Monica, Ortuño, Juan, Ariño, Inés, Domínguez-Muñoz, Juan Enrique, Perez-Aisa, Ángeles, Bermejo, Fernando, Domínguez, Jose Luis, Almela, Pedro, Gomez-Camarero, Judith, Millastre, Judith, Martin-Noguerol, Elisa, Gravina, Antonietta G., Martorano, Marco, Miranda, Agnese, Federico, Alessandro, Fernandez-Bermejo, Miguel, Angueira, Teresa, Ferrer-Barcelo, Luis, Fernández, Nuria, Marín, Alicia C., and McNicholl, Adrián G.

Published
2015
Full Text
View/download PDF

5. 123 - OPTIMIZACIÓN DE LA DOSIS DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN LOS TRATAMIENTOS ERRADICADORES DE PRIMERA Y SEGUNDA LÍNEA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Keco-Huerga, Alma, primary, Pabón-Carrasco, Manuel, additional, Castro-Fernández, Manuel, additional, Saracino, Ilaria Maria, additional, Fiorini, Giulia, additional, Vaira, Dino, additional, Pérez-Aísa, Ángeles, additional, Tepes, Bojan, additional, Jonaitis, Laimas, additional, Voynovan, Irina, additional, Lucendo, Alfredo J, additional, Lanas, Ángel, additional, Martínez-Domínguez, Samuel J, additional, Almajano, Enrique Alfaro, additional, Rodrigo, Luis, additional, Vologzanina, Ludmila, additional, Jurecic, Natasa Brglez, additional, Denkovski, Maja, additional, Bujanda, Luis, additional, Abdulkhakov, Rustam A, additional, Huguet, José M., additional, Salazar, L. Fernández, additional, Alcaide, Noelia, additional, Velayos, Benito, additional, Sarsenbaeva, Aiman Silkanovna, additional, Zaytsev, Oleg, additional, Ilchishina, Tatiana, additional, Barrio, Jesús, additional, Bakulin, Igor, additional, Perona, Monica, additional, Alekseenko, Sergey, additional, Romano, Marco, additional, Gravina, Antonietta G., additional, Núñez, Óscar, additional, Rodríguez, Blas José Gómez, additional, Ledro-Cano, Diego, additional, Pellicano, Rinaldo, additional, Bogomolov, Pavel, additional, Domínguez-Cajal, Manuel, additional, Almela, Pedro, additional, Gomez-Camarero, Judith, additional, Bordin, Dmitry S., additional, Gasbarrini, Antonio, additional, Kupinskas, Juozas, additional, Cano-Català, Anna, additional, Moreira, Leticia, additional, Nyssen, Olga P., additional, Mégraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2023
Full Text
View/download PDF

6. Role of proton pump inhibitors dosage and duration in Helicobacter pylorieradication treatment: Results from the European Registry on H. pylorimanagement

Author

Pabón‐Carrasco, Manuel, Keco‐Huerga, Alma, Castro‐Fernández, Manuel, Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez‐Aísa, Ángeles, Tepes, Bojan, Jonaitis, Laimas, Voynovan, Irina, Lucendo, Alfredo J., Lanas, Ángel, Martínez‐Domínguez, Samuel J., Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Brglez Jurecic, Natasa, Denkovski, Maja, Bujanda, Luis, Abdulkhakov, Rustam A., Huguet, Jose M., Fernández‐Salazar, Luis, Alcaide, Noelia, Velayos, Benito, Silkanovna Sarsenbaeva, Aiman, Zaytsev, Oleg, Ilchishina, Tatiana, Barrio, Jesús, Bakulin, Igor, Perona, Monica, Alekseenko, Sergey, Romano, Marco, Gravina, Antonietta G., Núñez, Óscar, Gómez Rodríguez, Blas José, Ledro‐Cano, Diego, Pellicano, Rinaldo, Bogomolov, Pavel, Domínguez‐Cajal, Manuel, Almela, Pedro, Gomez‐Camarero, Judith, Bordin, Dmitry S., Gasbarrini, Antonio, Kupčinskas, Juozas, Cano‐Català, Anna, Moreira, Leticia, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, Gisbert, Javier P., Tejedor‐Tejada, Javier, Tarasova, Galina, Dekhnich, Natalia Nikolaevna, Di Leo, Alfredo, Losurdo, Giuseppe, Fernández‐Bermejo, Miguel, Iyo, Eduardo, Bermejo, Fernando, Algaba, Alicia, Grigorieva, Ludmila, Lamuela Calvo, Luis Javier, Jiménez, Itxaso, Starostin, Boris D., Baryshnikova, Natalia, Peña‐Negro, Luisa C., Planella, Montserrat, Ramirez, Consuelo, Bakanova, Natalia V., Farinati, Fabio, Ghisa, Matteo, Angueira, Teresa, Kononova, Alla, Campillo, Ana, Villarroya, Ramón Pajares, Gomez, Barbara, Belousova, Liya Nikolaevna, Compare, Debora, Alcedo, Javier, Burgos‐Santamaría, Diego, Rancel‐Medina, Francisco‐José, Pérez‐Martínez, Isabel, Maev, Igor, Andreev, Dmitrii, González‐Santiago, Jesús M., Segarra Ortega, José Xavier, Flores, Virginia, Cuadrado‐Lavín, Antonio, and Hernández, Luis

Abstract

Management of Helicobacter pylori(H. pylori) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication. To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylorieradication treatments based on the ‘European Registry on Helicobacter pylorimanagement’ (Hp‐EuReg). Hp‐EuReg is a multicentre, prospective, non‐interventionist, international registry on the routine clinical practice of H. pylorimanagement by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022. Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first‐line‐modified intention‐to‐treat effectiveness was achieved with the following treatments: (1) 14‐day therapies with clarithromycin‐amoxicillin‐bismuth and metronidazole‐tetracycline‐bismuth, both independently of the PPI dose prescribed; (2) All 10‐day (except 10‐day standard triple therapy) and 14‐day therapies with high‐dose PPIs; and (3) 10‐day quadruple therapies with clarithromycin‐amoxicillin‐bismuth, metronidazole‐tetracycline‐bismuth, and clarithromycin‐amoxicillin‐metronidazole (sequential), all with standard‐dose PPIs. In first‐line treatment, optimal effectiveness was obtained with high‐dose PPIs in all 14‐day treatments, in 10‐ and 14‐day bismuth quadruple therapies and in 10‐day sequential with standard‐dose PPIs. Optimal second‐line effectiveness was achieved with (1) metronidazole‐tetracycline‐bismuth quadruple therapy for 14‐ and 10 days with standard and high‐dose PPIs, respectively; and (2) levofloxacin‐amoxicillin triple therapy for 14 days with high‐dose PPIs. None of the 7‐day therapies in both treatment lines achieved optimal effectiveness. We recommend, in first‐line treatment, the use of high‐dose PPIs in 14‐day triple therapy and in 10‐or 14‐day quadruple concomitant therapy in first‐line treatment, while standard‐dose PPIs would be sufficient in 10‐day bismuth quadruple therapies. On the other hand, in second‐line treatment, high‐dose PPIs would be more beneficial in 14‐day triple therapy with levofloxacin and amoxicillin or in 10‐day bismuth quadruple therapy either as a three‐in‐one single capsule or in the traditional scheme.

Published
2024
Full Text
View/download PDF

7. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

Author

Nyssen, Olga P., primary, Vaira, Dino, additional, Pérez Aísa, Ángeles, additional, Rodrigo, Luis, additional, Castro-Fernandez, Manuel, additional, Jonaitis, Laimas, additional, Tepes, Bojan, additional, Vologzhanina, Liudmila, additional, Caldas, María, additional, Lanas, Angel, additional, Lucendo, Alfredo J., additional, Bujanda, Luis, additional, Ortuño, Juan, additional, Barrio, Jesús, additional, Huguet, Jose M., additional, Voynovan, Irina, additional, Lasala, Jorge Perez, additional, Sarsenbaeva, Aiman Silkanovna, additional, Fernandez-Salazar, Luis, additional, Molina-Infante, Javier, additional, Jurecic, Natasa Brglez, additional, Areia, Miguel, additional, Gasbarrini, Antonio, additional, Kupčinskas, Juozas, additional, Bordin, Dmitry, additional, Marcos-Pinto, Ricardo, additional, Lerang, Frode, additional, Leja, Marcis, additional, Buzas, Gyorgy M., additional, Niv, Yaron, additional, Rokkas, Theodore, additional, Phull, Perminder, additional, Smith, Sinead, additional, Shvets, Oleg, additional, Venerito, Marino, additional, Milivojevic, Vladimir, additional, Simsek, Ilkay, additional, Lamy, Vincent, additional, Bytzer, Peter, additional, Boyanova, Lyudmila, additional, Kunovský, Lumír, additional, Beglinger, Christoph, additional, Doulberis, Michael, additional, Marlicz, Wojciech, additional, Goldis, Adrian, additional, Tonkić, Ante, additional, Capelle, Lisette, additional, Puig, Ignasi, additional, Megraud, Francis, additional, Morain, Colm O’, additional, Gisbert, Javier P., additional, Fiorinni, Giulia, additional, Saracino, Ilaria Maria, additional, Carrasco, Manuel Pabon, additional, Huerga, Alma Keco, additional, Almajano, Enrique Alfaro, additional, Martinez Dominguez, Samuel Jesus, additional, Galan, Horacio Alonso, additional, Velayos, Benito, additional, Sadornil, Carmen Dueñas, additional, Botargues Bote, Jose Maria, additional, Gonzalez-Cordero, Pedro Luis, additional, Gomez Rodriguez, Blas Jose, additional, Pellicano, Rinaldo, additional, Nuñez, Óscar, additional, Franceschi, Francesco, additional, Alekseenko, Sergey, additional, Perona, Monica, additional, Abdulkhakov, Rustam, additional, Dominguez-Cajal, Manuel, additional, Notari, Pedro Almela, additional, Camarero, Judith Gomez, additional, Moreno, Manuel Jimenez, additional, Algaba, Alicia, additional, Bermejo, Fernando, additional, Tejada, Javier Tejedor, additional, Susanibar, Elida Oblitas, additional, Boltin, Doron, additional, Georgopoulos, Sotirios, additional, OMorain, Colm, additional, Qasim, Asghar, additional, Beales, Ian, additional, Bakulina, Natalia, additional, Fadeenko, Galina, additional, Malfertheiner, Peter, additional, Rosania, Rosa, additional, Ilchishina, Tatiana, additional, Bogomolov, Pavel, additional, Bakulin, Igor, additional, Zaytsev, Oleg, additional, Gravina, Antonietta Gerarda, additional, Romano, Marco, additional, Di Leo, Alfredo, additional, Losurdo, Giuseppe, additional, Grigorieva, Ludmila, additional, Guillena, Pedro Delgado, additional, Marusic, Marinko, additional, Jurcic, Dragan, additional, Dekhnich, Natalia Nikolaevna, additional, Iyo, Eduardo, additional, de la Peña Negro, Luisa Carmen, additional, Baryshnikova, Natalia, additional, Bakanova, Natalia, additional, Simsek, Halis, additional, Simsek, Cem, additional, Gridnyev, Oleksiy, additional, Fernandez-Bermejo, Miguel, additional, Angueira, Teresa, additional, Ruiz-Zorrilla Lopez, Rafael, additional, Gomez, Barbara, additional, Kovacheva-Slavova, Mila, additional, Lahat, Adi, additional, Alcedo, Javier, additional, Campillo, Ana, additional, Belousova, Liya Nikolaevna, additional, Villarroya, Ramon Pajares, additional, Ljubicic, Neven, additional, Nikolic, Marko, additional, González-Santiago, Jesús M., additional, Santamaría, Diego Burgos, additional, Pakhomova, Anna, additional, Sekulic-Spasic, Izabela, additional, Ghisa, Matteo, additional, Farinati, Fabio, additional, Sagdati, Sabir Irfan, additional, Panic, Nikola, additional, Heluwaert, Frederic, additional, Amorena, Edurne, additional, Moreira, Leticia, additional, Esparrach, Gloria Fernandez, additional, Plotnikova, Ekaterina Yuryevna, additional, Kukla, Michal, additional, Kamburov, Victor, additional, Lamuela Calvo, Luis Javier, additional, Rankovic, Ivan, additional, Lavín, Antonio Cuadrado, additional, Lazaro, Yolanda Arguedas, additional, Carrera Agnieszka Dobrowolska, Victor Gonzalez, additional, Eder, Piotr, additional, and Kononova, Alla, additional

Published
2022
Full Text
View/download PDF

9. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Author

Caldas, Maria, Perez-Aisa, Angeles, Castro-Fernandez, Manuel, Bujanda, Luis, Lucendo, Alfredo J., Rodrigo, Luis, Huguet, Jose M., Perez-Lasala, Jorge, Molina-Infante, Javier, Barrio, Jesus, Fernandez-Salazar, Luis, Lanas, Angel, Perona, Monica, Dominguez-Cajal, Manuel, Ortuno, Juan, Gomez-Rodriguez, Blas Jose, Almela, Pedro, Botargues, Josep Maria, Nunez, Oscar, Modolell, Ines, Gomez, Judith, Ruiz-Zorrilla, Rafael, De la Coba, Cristobal, Huerta, Alain, Iyo, Eduardo, Pozzati, Liliana, Anton, Rosario, Barenys, Merce, Angueira, Teresa, Fernandez-Bermejo, Miguel, Campillo, Ana, Alcedo, Javier, Pajares-Villaroya, Ramon, Mego, Marianela, Bermejo, Fernando, Dominguez-Jimenez, Jose Luis, Tito, Llucia, Fernandez, Nuria, Pabon-Carrasco, Manuel, Cosme, Angel, Mata-Romero, Pilar, Alcaide, Noelia, Arino, Ines, Di Maira, Tommaso, Garre, Ana, Puig, Ignasi, Nyssen, Olga P., Megraud, Francis, O'Morain, Colm, Gisbert, Javier P., Hp EuReg Investigators, and UAM. Departamento de Medicina

Subjects
Microbiology (medical), second-line, Helicobacter pylori infection, medicine.medical_specialty, Multivariate analysis, Medicina, Therapeutics, Biochemistry, Microbiology, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, Moxifloxacin, Internal medicine, Medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, Medical prescription, first-line, Helicobacter pylori, Spain, first-line, second-line, treatment, Second line treatment, biology, Helicobacter pylori, treatment, business.industry, lcsh:RM1-950, Infeccions per Helicobacter pylori, biology.organism_classification, Terapèutica, Helicobacter pylori infections, bacterial infections and mycoses, Infectious Diseases, lcsh:Therapeutics. Pharmacology, Spain, 030220 oncology & carcinogenesis, Concomitant, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. &ldquo, Optimized&rdquo, H. pylori therapies achieve over 90% success in Spain.

Published
2021

10. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice

Author

Nyssen, Olga P, Perez-Aisa, Angeles, Castro-Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M, Rodrigo, Luis, Ortuñ, Juan, O, Gomez-Rodriguez, Blas J, Pinto, Ricardo M, Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gravina, Antonietta G, Pozzati, Liliana, Fernandez-Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez-Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O'Morain, Colm, Gisbert, Javier P, Hp-EuReg investigators, UAM. Departamento de Medicina, Nyssen O.P., Perez-Aisa A., Castro-Fernandez M., Pellicano R., Huguet J.M., Rodrigo L., Ortun J., Gomez-Rodriguez B.J., Pinto R.M., Areia M., Perona M., Nunez O., Romano M., Gravina A.G., Pozzati L., Fernandez-Bermejo M., Venerito M., Malfertheiner P., Fernanadez-Salazar L., Gasbarrini A., Vaira D., Puig I., Megraud F., O'Morain C., Gisbert J.P., Nyssen, Op, Perez-Aisa, A, Castro-Fernandez, M, Pellicano, R, Huguet, Jm, Rodrigo, L, Ortuño, J, Gomez-Rodriguez, Bj, Pinto, Rm, Areia, M, Perona, M, Nuñez, O, Romano, M, Gerarda Gravina, A, Pozzati, L, Fernandez-Bermejo, M, Venerito, M, Malfertheiner, P, Fernanadez-Salazar, L, Gasbarrini, A, Vaira, D, Puig, I, Megraud, F, O'Morain, C, and Gisbert, Jp

Subjects
Registrie, Male, Helicobacter pylori infection, Proton Pump Inhibitor, Intention to Treat Analysi, Gastrointestinal Diseases, Drug Resistance, Gastroenterology, Bismuth, 0302 clinical medicine, Drug Combination, eradication, Registries, Capsule, biology, Bacterial, Middle Aged, Anti-Bacterial Agents, Intention to Treat Analysis, Clinical Practice, Europe, Drug Combinations, Oncology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Female, Original Article, Human, medicine.drug, inorganic chemicals, Adult, medicine.medical_specialty, Adolescent, Medicina, medicine.drug_class, Tetracycline, Gastrointestinal Disease, Settore MED/12 - GASTROENTEROLOGIA, quadruple, Proton-pump inhibitor, chemistry.chemical_element, Capsules, digestive system, Helicobacter Infections, Medication Adherence, Neurogastroenterology, 03 medical and health sciences, Young Adult, Internal medicine, Metronidazole, Anti-Bacterial Agent, Drug Resistance, Bacterial, bismuth, medicine, Humans, Helicobacter pylori, business.industry, Settore MED/09 - MEDICINA INTERNA, Proton Pump Inhibitors, equipment and supplies, bacterial infections and mycoses, biology.organism_classification, Pylera, digestive system diseases, chemistry, business, Helicobacter Infection
Abstract

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Background: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation. Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy. Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile, The author(s) would like to thank the Spanish Association of Gastroenterology (AEG) for providing the electronic case report form service free of charge. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was promoted and funded by the European Helicobacterand Microbiota Study Group, and received support from the Spanish Association of Gastroenterology (AEG) and the Centro de Investigación Biomedica en Red de Enfermedades Hepaticas y Digestivas

Published
2020

11. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)

Author

Nyssen, Olga P., primary, Perez-Aisa, Angeles, additional, Tepes, Bojan, additional, Castro-Fernandez, Manuel, additional, Kupcinskas, Juozas, additional, Jonaitis, Laimas, additional, Bujanda, Luis, additional, Lucendo, Alfredo, additional, Jurecic, Natasa Brglez, additional, Perez-Lasala, Jorge, additional, Shvets, Oleg, additional, Fadeenko, Galina, additional, Huguet, Jose M., additional, Kikec, Zdenki, additional, Bordin, Dmitry, additional, Voynovan, Irina, additional, Leja, Marcis, additional, Machado, Jose Carlos, additional, Areia, Miguel, additional, Fernandez-Salazar, Luis, additional, Rodrigo, Luis, additional, Alekseenko, Sergey, additional, Barrio, Jesus, additional, Ortuño, Juan, additional, Perona, Monica, additional, Vologzhanina, Liudmila, additional, Romero, Pilar Mata, additional, Zaytsev, Oleg, additional, Rokkas, Theodore, additional, Georgopoulos, Sotirios, additional, Pellicano, Rinaldo, additional, Buzas, Gyorgy M., additional, Modolell, Ines, additional, Gomez Rodriguez, Blas Jose, additional, Simsek, Ilkay, additional, Simsek, Cem, additional, Lafuente, Marina Roldan, additional, Ilchishina, Tatiana, additional, Camarero, Judith Gomez, additional, Dominguez-Cajal, Manuel, additional, Ntouli, Vassiliki, additional, Dekhnich, Natalia Nikolaevna, additional, Phull, Perminder, additional, Nuñez, Oscar, additional, Lerang, Frode, additional, Venerito, Marino, additional, Heluwaert, Frederic, additional, Tonkic, Ante, additional, Caldas, Maria, additional, Puig, Ignasi, additional, Megraud, Francis, additional, O'Morain, Colm, additional, and Gisbert, Javier P., additional

Published
2021
Full Text
View/download PDF

12. 135 - TENDENCIAS DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE A LO LARGO DE 10 AÑOS (2013-2022) EN EUROPA: DATOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Nyssen, Olga P., Jonaitis, Laimas, Pérez-Aísa, Ángeles, Vaira, Dino, Fiorini, Giulia, Saracino, Ilaria Maria, Tepes, Bojan, Bordin, Dmitry, Huerga, Alma Keco, Castro-Fernández, Manuel, Lucendo, Alfredo, Vologzhanina, Liudmila, Bujanda, Luis, Jurecic, Natasa Brglez, Denkovski, Maja, Lanas, Angel, Martínez-Dominguez, Samuel, Alfaro, Enrique, Leja, Marcis, Bumane, Renate, Mammadov, Emin, Babayeva, Gulustan, Mahmudov, Umud, Caldas, María, Rodrigo, Luis, Lerang, Frode, Fadieienko, Galyna, Abdulkhakov, Rustam, Malavés, Jose María Huguet, Zaytsev, Oleg, Ilchishina, Tatiana, Fernández-Salazar, Luis, Alcaide, Noelia, Velayos, Benito, Sarsenbaeva, Aiman Silkanovna, Bakulin, Igor, Gravina, Antonietta G., Romano, Marco, Perona, Mónica, Alekseenko, Sergey, Barrio, Jesús, Areia, Miguel, Nuñez, Óscar, Bogomolov, Pavel, Rodríguez, Blas José Gómez, Cajal, Manuel Dominguez, Camarero, Judith Gomez, Moreno, Manuel Jiménez, Georgopoulos, Sotirios, Notari, Pedro Almela, Tonkic, Ante, Pellicano, Rinaldo, Simsek, Halis, Kunovský, Lumír, Gasbarrini, Antonio, Bote, Jose Maria Botargues, Buzas, Gyorgy M, Fernández-Bermejo, Miguel, Phull, Perminder, Venerito, Marino, Malfertheiner, Peter, Rosania, Rosa, Link, Alexander, Iyo, Eduardo, Kupinskas, Juozas, Shvets, Oleg, Pinto, Ricardo Marcos, Rokkas, Theodore, Simsek, Ilkay, Smith, Sinead, Boltin, Doron, Lamarque, Dominique, Dobru, Daniela, Marlicz, Wojciech, Milivojevic, Vladimir, Boyanova, Lyudmila, Lamy, Vincent, Doulberis, Michael, Bytzer, Peter, Capelle, Lisette, Gridnyev, Oleksiy, Ristimaki, Ari, Cano-Català, Anna, Puig, Ignasi, Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

13. 139 - EFECTIVIDAD EN SEGUNDA LÍNEA DE TRATAMIENTO FRENTE A HELICOBACTER PYLORI: SUBANÁLISIS DE LOS DATOS ESPAÑOLES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HPEUREG)

Author

Hernández, Luis, Pérez-Aisa, Maria Ángeles, Domínguez, Samuel Jesús Martínez, Pabón-Carrasco, Manuel, Bujanda, Luis, Lucendo, Alfredo, Rodrigo, Luis, Garre, Ana, Huguet, Jose María, Alcaide, Noelia, Perona, Mónica, Barrio, Jesús, Núñez, Óscar, Tejada, Javier Tejedor, Mata, Pilar, Ledro, Diego, Ortuño, Juan, Cajal, Manuel Domínguez, Ladrón, Gema, Camarero, Judith Gómez, Rodríguez, Blas José Gómez, Nyssen, Olga P., Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

14. 138 - EFECTIVIDAD EN PRIMERA LÍNEA DE TRATAMIENTO FRENTE A HELICOBACTER PYLORI: SUBANÁLISIS DE LOS DATOS ESPAÑOLES DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HPEUREG)

Author

Hernández, Luis, Pérez-Aisa, Maria Ángeles, Domínguez, Samuel Jesús Martínez, Pabón-Carrasco, Manuel, Bujanda, Luis, Lucendo, Alfredo, Rodrigo, Luis, Garre, Ana, Huguet, Jose María, Alcaide, Noelia, Perona, Mónica, Barrio, Jesús, Núñez, Óscar, Tejada, Javier Tejedor, Mata, Pilar, Ledro, Diego, Ortuño, Juan, Cajal, Manuel Domínguez, Ladrón, Gema, Camarero, Judith Gómez, Rodríguez, Blas José Gómez, Nyssen, Olga P., Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

15. 128 - TENDENCIAS TEMPORALES DE PRESCRIPCIÓN DE TRATAMIENTOS ERRADICADORES Y DE SU EFECTIVIDAD EN PACIENTES NAÏVE EN ESPAÑA ENTRE 2013 Y 2022: 10 AÑOS DE EXPERIENCIA DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR H. PYLORI (HP-EUREG)

Author

Hernández, Luis, Pérez-Aisa, Maria Ángeles, Domínguez, Samuel Jesús Martínez, Pabón-Carrasco, Manuel, Bujanda, Luis, Lucendo, Alfredo, Rodrigo, Luis, Garre, Ana, Huguet, Jose María, Alcaide, Noelia, Perona, Mónica, Barrio, Jesús, Núñez, Óscar, Tejada, Javier Tejedor, Mata, Pilar, Ledro, Diego, Ortuño, Juan, Cajal, Manuel Dominguez, Ladrón, Gema, Camarero, Judith Gómez, Rodríguez, Blas José Gómez, Nyssen, Olga P., Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

16. LA ADMINISTRACIÓN DE LA TERAPIA CUÁDRUPLE CON BISMUTO EN CÁPSULA ÚNICA TRES VECES AL DÍA AUMENTA LA EFICACIA EN COMPARACIÓN CON LA PAUTA CONVENCIONAL DE CUATRO DOSIS DIARIAS: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)

Author

Pérez-Aísa, Ángeles, Nyssen, Olga P., Keco-Huerga, Alma, Rodrigo, Luis, Lucendo, Alfredo J, Rodríguez, Blas José Gómez, Ortuño, Juan, Perona, Mónica, Huguet, José M., Núñez, Óscar, Fernández-Salazar, Luis, Barrio, Jesús, Lanas, Ángel, Iyo, Eduardo, Romero, Pilar Mata, Bermejo, Miguel Fernández, Gomez, Barbara, Garre, Ana, Gomez-Camarero, Judith, Lamuela, Luis Javier, Campillo, Ana, de la Peña-Negro, Luisa C, Dominguez-Cajal, Manuel, Bujanda, Luis, Burgos-Santamaria, Diego, Bermejo, Fernando, González-Carrera, Víctor, Pajares, Ramón, Notari, Pedro Almela, Tejedor-Tejada, Javier, Planella, Montserrat, Jiménez, Itxaso, Lázaro, Yolanda Arguedas, Cuadrado-Lavín, Antonio, Pérez-Martínez, Isabel, Amorena, Edurne, Santiago, Jesús M González, Angueira, Teresa, Flores, Virginia, Martínez-Domínguez, Samuel Jesús, Pabón-Carrasco, Manuel, Velayos, Benito, Algaba, Alicia, Ramírez, Consuelo, Almajano, Enrique Alfaro, Castro-Fernández, Manuel, Alcaide, Noelia, Segura, Patricia Sanz, Cano-Català, Anna, Morales, Natalia García, Moreira, Leticia, Mégraud, Francis, O’Morain, Colm, Calvet, Xavier, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

17. Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg)

Author

Nyssen, Olga P., primary, Perez‐Aisa, Angeles, additional, Rodrigo, Luis, additional, Castro, Manuel, additional, Mata Romero, Pilar, additional, Ortuño, Juan, additional, Barrio, Jesus, additional, Huguet, Jose Maria, additional, Modollel, Ines, additional, Alcaide, Noelia, additional, Lucendo, Alfredo, additional, Calvet, Xavier, additional, Perona, Monica, additional, Gomez, Barbara, additional, Gomez Rodriguez, Blas Jose, additional, Varela, Pilar, additional, Jimenez‐Moreno, Manuel, additional, Dominguez‐Cajal, Manuel, additional, Pozzati, Liliana, additional, Burgos‐Santamaria, Diego, additional, Bujanda, Luis, additional, Hinojosa, Jenifer, additional, Molina‐Infante, Javier, additional, Di Maira, Tommaso, additional, Ferrer, Luis, additional, Fernández‐Salazar, Luis, additional, Figuerola, Ariadna, additional, Tito, Llucia, additional, Coba, Cristobal, additional, Gomez‐Camarero, Judith, additional, Fernandez, Nuria, additional, Caldas, Maria, additional, Garre, Ana, additional, Resina, Elena, additional, Puig, Ignasi, additional, O’Morain, Colm, additional, Megraud, Francis, additional, and Gisbert, Javier P., additional

Published
2020
Full Text
View/download PDF

21. sj-pdf-1-ueg-10.1177_2050640620972615 - Supplemental material for European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice

Author

Nyssen, Olga P, Angeles Perez-Aisa, Castro-Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M., Rodrigo, Luis, Ortuño, Juan, Gomez-Rodriguez, Blas Jose, Pinto, Ricardo Marcos, Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gravina, Antonietta Gerarda, Pozzati, Liliana, Fernandez-Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez-Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620972615 for European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice by Olga P Nyssen, Angeles Perez-Aisa, Manuel Castro-Fernandez, Rinaldo Pellicano, Jose M. Huguet, Luis Rodrigo, Juan Ortuño, Blas Jose Gomez-Rodriguez, Ricardo Marcos Pinto, Miguel Areia, Monica Perona, Oscar Nuñez, Marco Romano, Antonietta Gerarda Gravina, Liliana Pozzati, Miguel Fernandez-Bermejo, Marino Venerito, Peter Malfertheiner, Luis Fernanadez-Salazar, Antonio Gasbarrini, Dino Vaira, Ignasi Puig, Francis Megraud, Colm O’Morain and Javier P Gisbert in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

22. sj-pdf-2-ueg-10.1177_2050640620972615 - Supplemental material for European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice

Author

Nyssen, Olga P, Angeles Perez-Aisa, Castro-Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M., Rodrigo, Luis, Ortuño, Juan, Gomez-Rodriguez, Blas Jose, Pinto, Ricardo Marcos, Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gravina, Antonietta Gerarda, Pozzati, Liliana, Fernandez-Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez-Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-2-ueg-10.1177_2050640620972615 for European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple therapy is effective in real-world clinical practice by Olga P Nyssen, Angeles Perez-Aisa, Manuel Castro-Fernandez, Rinaldo Pellicano, Jose M. Huguet, Luis Rodrigo, Juan Ortuño, Blas Jose Gomez-Rodriguez, Ricardo Marcos Pinto, Miguel Areia, Monica Perona, Oscar Nuñez, Marco Romano, Antonietta Gerarda Gravina, Liliana Pozzati, Miguel Fernandez-Bermejo, Marino Venerito, Peter Malfertheiner, Luis Fernanadez-Salazar, Antonio Gasbarrini, Dino Vaira, Ignasi Puig, Francis Megraud, Colm O’Morain and Javier P Gisbert in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

23. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin:Experience from the European Registry on H pylori management (Hp-EuReg)

Author

Nyssen, Olga P., Pérez-Aisa, Ángeles, Tepes, Bojan, Rodrigo-Sáez, Luis, Romero, Pilar M., Lucendo, Alfredo, Castro-Fernández, Manuel, Phull, Perminder, Barrio, Jesús, Bujanda, Luis, Ortuño, Juan, Areia, Miguel, Brglez Jurecic, Natasa, Huguet, José María, Alcaide, Noelia, Voynovan, Irina, María Botargues Bote, José, Modolell, Inés, Pérez Lasala, Jorge, Ariño, Inés, Jonaitis, Laimas, Dominguez-Cajal, Manuel, Buzas, György, Lerang, Frode, Perona, Monica, Bordin, Dmitry, Axon, Toni, Gasbarrini, Antonio, Marcos Pinto, Ricardo, Niv, Yaron, Kupcinskas, Limas, Tonkic, Ante, Leja, Marcis, Rokkas, Theodore, Boyanova, Lyudmila, Shvets, Oleg, Venerito, Marino, Bytzer, Peter, Goldis, Adrian, Simsek, Ilkay, Lamy, Vincent, Przytulski, Krzysztof, Kunovský, Lumír, Capelle, Lisette, Milosavljevic, Tomica, Caldas, María, Garre, Ana, Mégraud, Francis, O'Morain, Colm, Gisbert, Javier P., Nyssen, Olga P., Pérez-Aisa, Ángeles, Tepes, Bojan, Rodrigo-Sáez, Luis, Romero, Pilar M., Lucendo, Alfredo, Castro-Fernández, Manuel, Phull, Perminder, Barrio, Jesús, Bujanda, Luis, Ortuño, Juan, Areia, Miguel, Brglez Jurecic, Natasa, Huguet, José María, Alcaide, Noelia, Voynovan, Irina, María Botargues Bote, José, Modolell, Inés, Pérez Lasala, Jorge, Ariño, Inés, Jonaitis, Laimas, Dominguez-Cajal, Manuel, Buzas, György, Lerang, Frode, Perona, Monica, Bordin, Dmitry, Axon, Toni, Gasbarrini, Antonio, Marcos Pinto, Ricardo, Niv, Yaron, Kupcinskas, Limas, Tonkic, Ante, Leja, Marcis, Rokkas, Theodore, Boyanova, Lyudmila, Shvets, Oleg, Venerito, Marino, Bytzer, Peter, Goldis, Adrian, Simsek, Ilkay, Lamy, Vincent, Przytulski, Krzysztof, Kunovský, Lumír, Capelle, Lisette, Milosavljevic, Tomica, Caldas, María, Garre, Ana, Mégraud, Francis, O'Morain, Colm, and Gisbert, Javier P.

Abstract

Background: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim: To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the “European Registry of H pylori management” (Hp-EuReg). Methods: A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019. Results: One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera®; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P <.001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P >.05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases. Conclusion: In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results.

Published
2020

24. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study

Author

Molina-Infante, Javier, Gutierrez-Junquera, Carolina, Savarino, Edoardo, Penagini, Roberto, Modolell, Ines, Bartolo, Ottavia, Prieto-García, Alicia, Mauro, Aurelio, Alcedo, Javier, Perelló, Antonia, Guarner-Argente, Carlos, Alcaide, Noelia, Vegas, Ana M., Barros-García, Patricia, Murzi-Pulgar, Marianette, Perona, Monica, Gisbert, Javier P., Lucendo, Alfredo J., de Bortoli, Nicola, Costa, Valeria A., Dominguez-Jimenez, Jose Luis, Garcia-Romero, Ruth, Jimeno, Cristina, Marabotto, Elisa, Pajares-Diaz, Jose Antonio, Perez-Aisa, Angeles, Tolone, Salvatore, Ortiz, Vicente, Zerbib, Frank, Galera, Ana Pilar, Molina-Infante, Javier, Gutierrez-Junquera, Carolina, Savarino, Edoardo, Penagini, Roberto, Modolell, Ine, Bartolo, Ottavia, Prieto-García, Alicia, Mauro, Aurelio, Alcedo, Javier, Perelló, Antonia, Guarner-Argente, Carlo, Alcaide, Noelia, Vegas, Ana M., Barros-García, Patricia, Murzi-Pulgar, Marianette, Perona, Monica, Gisbert, Javier P., Lucendo, Alfredo J., de Bortoli, Nicola, Costa, Valeria A., Dominguez-Jimenez, Jose Lui, Garcia-Romero, Ruth, Jimeno, Cristina, Marabotto, Elisa, Pajares-Diaz, Jose Antonio, Perez-Aisa, Angele, Tolone, Salvatore, Ortiz, Vicente, Zerbib, Frank, and Galera, Ana Pilar

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Colombia, Gastroenterology, Hepatology, Serology, Helicobacter Infections, Atopy, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Prevalence, Medicine, Humans, Prospective Studies, Prospective cohort study, Eosinophilic esophagitis, Child, Asthma, Aged, biology, Helicobacter pylori, business.industry, Case-control study, Age Factors, Odds ratio, Eosinophilic Esophagitis, Middle Aged, medicine.disease, biology.organism_classification, Italy, Spain, 030220 oncology & carcinogenesis, Case-Control Studies, 030211 gastroenterology & hepatology, Female, France, business
Abstract

Objectives: Rising trends in eosinophilic esophagitis (EoE) have been repeatedly linked to declining Helicobacter pylori (H. pylori) infection, mostly in retrospective studies. We aimed to prospectively evaluate this inverse association. Methods: Prospective case-control study conducted in 23 centers. Children and adults naïve to eradication therapy for H. pylori were included. Cases were EoE patients, whereas controls were defined by esophageal symptoms and

Published
2017

25. Non-acid reflux and sleep apnea: the importance of drug induced sleep endoscopy.

Author

O'Connor-Reina, Carlos, Garcia, Jose Maria Ignacio, Baptista, Peter, Garcia-Iriarte, Maria Teresa, Alba, Carlos Casado, Perona, Monica, Borrmann, Paz Francisca, Alcala, Laura Rodriguez, and Plaza, Guillermo

Subjects
GASTROESOPHAGEAL reflux diagnosis, ESOPHAGOSCOPY, MANOMETERS, PROTON pump inhibitors, SLEEP apnea syndromes, LARYNGEAL diseases, ALGINATES, BIOELECTRIC impedance, QUESTIONNAIRES, ENDOSCOPY
Abstract

Background: We present the first case of a patient with obstructive sleep apnea syndrome (OSA), where drug induced sleep endoscopy was helpful to suspect a non-acid reflux disease and showed an improvement in a swollen epiglottis after treatment. Patient ameliorated significantly his disease only with medical therapy. Case presentation: A 54-year-old man without significant anatomical findings with obstructive sleep apnea syndrome and non-acid gastroesophageal reflux disease (GERD) disease whose Apnea- hypopnea index (AHI) was significantly reduced with the intake of 500 mg of sodium alginate twice a day for 6 months. Conventional digestive tests such as esophagoscopy and simple- and double-channel 24-h pH-metry suggested mild GERD. Conventional proton-pump inhibitor treatment with pantoprazole (40 mg daily) was started without any improvement in his sleep. Multichannel intraluminal 24-h impedanciometry indicated the presence of severe pathological GER of gaseous origin. The patient's AHI decreased from 25.3 at baseline to 8 after treatment with sodium alginate. A drug-induced sleep endoscopy study showed the changes before and after this treatment and was helpful for the diagnosis. Conclusions: Thus, medical treatment can be a therapeutic option in some patients with OSA. Multichannel 24-h impedanciometry should be performed when nonacid GERD is suspected. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Cyp2c19 Genotype and Response to Proton Pump Inhibitor Therapy in Naãÿve Adult Patients with Eosinophilic Esophagitis

Author

Gonzalez-Cordero, Pedro L., primary, Rivas, Maria Dolores, additional, Arias, Ángel, additional, Rodrigo, Luis, additional, Barrio, Jesús, additional, Nantes, Óscar, additional, Flores, Alexander, additional, Perona, Monica C., additional, Rodríguez-Téllez, Manuel, additional, Zamorano, Jose, additional, Lucendo, Alfredo, additional, and Molina-Infante, Javier, additional

Published
2017
Full Text
View/download PDF

27. European Registry on Helicobacter pylorimanagement: Single‐capsule bismuth quadruple therapy is effective in real‐world clinical practice

Author

Nyssen, Olga P., Perez‐Aisa, Angeles, Castro‐Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M., Rodrigo, Luis, Ortuñ, Juan, o, Gomez‐Rodriguez, Blas J., Pinto, Ricardo M., Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gravina, Antonietta G., Pozzati, Liliana, Fernandez‐Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez‐Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O'Morain, Colm, and Gisbert, Javier P.

Abstract

There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pyloriinfection thanks to a three‐in‐one single‐capsule formulation. To evaluate the effectiveness and safety of the single‐capsule bismuth quadruple therapy. Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pyloriinfection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention‐to‐treat and per‐protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line. Finally, 2100 patients were prescribed single‐capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention‐to‐treat effectiveness of 92% was achieved. Eradication was over 90% in first‐line treatment (95% modified intention‐to‐treat, n= 1166), and this was maintained as a rescue therapy, both in second (89% modified intention‐to‐treat, n= 375) and subsequent lines of therapy (third to sixth line: 92% modified intention‐to‐treat, n= 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases. Single‐capsule bismuth quadruple therapy achieved H. pylorieradication in approximately 90% of patients in real‐world clinical practice, both as a first‐line and rescue treatment, with good compliance and a favourable safety profile. The development of a three‐in‐one single‐capsule formulation has led to a resurgence in the use of bismuth quadruple therapy (BQT) to treat Helicobacter pyloriinfection.In the largest study carried out to date, the effectiveness of single‐capsule BQT was optimal both as a firstline and as a rescue therapy.Compliance was the factor most closely associated with treatment effectiveness.Single‐capsule BQT eradicates H. pyloriin approximately 90% of patients in real‐world clinical practice, with a favourable safety profile. The development of a three‐in‐one single‐capsule formulation has led to a resurgence in the use of bismuth quadruple therapy (BQT) to treat Helicobacter pyloriinfection. In the largest study carried out to date, the effectiveness of single‐capsule BQT was optimal both as a firstline and as a rescue therapy. Compliance was the factor most closely associated with treatment effectiveness. Single‐capsule BQT eradicates H. pyloriin approximately 90% of patients in real‐world clinical practice, with a favourable safety profile.

Published
2021
Full Text
View/download PDF

28. Mo1173 Association Between Eosinophilic Esophagitis and Helicobacter pylori Infection: Preliminary Results of a Multicenter Study

Author

Molina-Infante, Javier, primary, Savarino, Edoardo, additional, Modolell, Ines, additional, Penagini, Roberto, additional, Mauro, Aurelio, additional, Ottavia, Bartolo, additional, Marabotto, Elisa, additional, Tolone, Salvatore, additional, de Bortoli, Nicola, additional, Perona, Monica C., additional, Domínguez, Jose Luis, additional, Aisa, Angeles Perez, additional, Zerbib, Frank, additional, Lucendo, Alfredo J., additional, and Gisbert, Javier P., additional

Published
2016
Full Text
View/download PDF

29. Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies

Author

Caldas, Maria, primary, Aisa, Angeles Perez, additional, Castro-Fernandez, Manuel, additional, Bujanda, Luis, additional, Rodrigo, Luis, additional, Hinojosa, J, additional, Perez-Lasala, Jorge, additional, Lanas, Angel, additional, Molina-Infante, Javier, additional, Domínguez-Cajal, Manuel, additional, Almela, Pedro, additional, Barrio, Jesús, additional, Botargues, Josep M., additional, Salazar, Luis Fernandez, additional, Modolell, Ines, additional, Lucendo, Alfredo J., additional, Ortuño, Juan, additional, Ruiz-Zorrilla, Rafael, additional, De la Coba, Cristobal, additional, Barenys, M, additional, Alcedo, J, additional, Perona, Monica C., additional, Gómez, J, additional, Bermejo, F, additional, Pajares, R., additional, Pozzati, Liliana, additional, Rodríguez-Téllez, Manuel, additional, Gomez-Rodriguez, Blas-Jose, additional, Medina, Enrique, additional, Huguet, José María, additional, Barceló, Luis Ferrer, additional, Ramas, Mercedes, additional, O'Morain, Colm A., additional, McNicholl, Adrian G., additional, and Gisbert, Javier P., additional

Published
2016
Full Text
View/download PDF

30. European Registry on Helicobacter pyloriManagement: single-capsule bismuth quadruple therapy is effective in real-world clinical practice

Author

Nyssen, Olga P, Perez-Aisa, Angeles, Castro-Fernandez, Manuel, Pellicano, Rinaldo, Huguet, Jose M., Rodrigo, Luis, Ortuño, Juan, Gomez-Rodriguez, Blas Jose, Pinto, Ricardo Marcos, Areia, Miguel, Perona, Monica, Nuñez, Oscar, Romano, Marco, Gerarda Gravina, Antonietta, Pozzati, Liliana, Fernandez-Bermejo, Miguel, Venerito, Marino, Malfertheiner, Peter, Fernanadez-Salazar, Luis, Gasbarrini, Antonio, Vaira, Dino, Puig, Ignasi, Megraud, Francis, O’Morain, Colm, and Gisbert, Javier P

Abstract

Background There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pyloriinfection thanks to a three-in-one single-capsule formulation.Objective To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy.Methods Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pyloriinfection, where patients were registered at the Asociación Española de Gastroenterología REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line.Results Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e. three capsules every 6 hours for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n= 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n= 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n= 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases.Conclusions Single-capsule bismuth quadruple therapy achieved H. pylorieradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile.

Published
2024
Full Text
View/download PDF

32. Su1149 Two-Week, High-Dose Proton Pump Inhibitor, Moxifloxacin Triple H. pylori Therapy After Failure of Standard Triple or Non-Bismuth Quadruple Treatments

Author

Gisbert, Javier P., Romano, Marco, Molina-Infante, Javier, Lucendo, Alfredo J., Chulia, Enrique Medina, Modolell, Ines, Rodríguez-Téllez, Manuel, Rodríguez, Blas Jose Gómez, Barrio, Jesus, Perona, Mónica, Ortuno, Juan A., Ariño, Ines, Domínguez-Muñoz, Juan Enrique, Aisa, Angeles Perez, Bermejo, Fernando, Domínguez-Jiménez, Jose Luis, Almela, Pedro, Gomez-Camarero, Judith, Millastre, Judith, Martin-Noguerol, Elisa, Gravina, Antonietta G., Martorano, Marco, Miranda, Agnese, Federico, Alessandro, Bermejo, Miguel Fernandez, Angueira, Teresa, Barceló, Luis Ferrer, Moreno, Nuria Fernandez, Marin, Alicia C, and McNicholl, Adrian G.

Published
2015
Full Text
View/download PDF

35. 123 - OPTIMIZACIÓN DE LA DOSIS DE LOS INHIBIDORES DE LA BOMBA DE PROTONES EN LOS TRATAMIENTOS ERRADICADORES DE PRIMERA Y SEGUNDA LÍNEA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)

Author

Keco-Huerga, Alma, Pabón-Carrasco, Manuel, Castro-Fernández, Manuel, Saracino, Ilaria Maria, Fiorini, Giulia, Vaira, Dino, Pérez-Aísa, Ángeles, Tepes, Bojan, Jonaitis, Laimas, Voynovan, Irina, Lucendo, Alfredo J, Lanas, Ángel, Martínez-Domínguez, Samuel J, Almajano, Enrique Alfaro, Rodrigo, Luis, Vologzanina, Ludmila, Jurecic, Natasa Brglez, Denkovski, Maja, Bujanda, Luis, Abdulkhakov, Rustam A, Huguet, José M., Salazar, L. Fernández, Alcaide, Noelia, Velayos, Benito, Sarsenbaeva, Aiman Silkanovna, Zaytsev, Oleg, Ilchishina, Tatiana, Barrio, Jesús, Bakulin, Igor, Perona, Monica, Alekseenko, Sergey, Romano, Marco, Gravina, Antonietta G., Núñez, Óscar, Rodríguez, Blas José Gómez, Ledro-Cano, Diego, Pellicano, Rinaldo, Bogomolov, Pavel, Domínguez-Cajal, Manuel, Almela, Pedro, Gomez-Camarero, Judith, Bordin, Dmitry S., Gasbarrini, Antonio, Kupinskas, Juozas, Cano-Català, Anna, Moreira, Leticia, Nyssen, Olga P., Mégraud, Francis, O’Morain, Colm, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

36. Su1164 Second-Line Rescue Therapy With Moxifloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection

Author

Gisbert, Javier P., Romano, Marco, Molina-Infante, Javier, Lucendo, Alfredo J., Chulia, Enrique Medina, Modolell, Ines, Rodriguez, Blas J. Gómez, Barrio, Jesus, Perona, Mónica, Ortuno, Juan A., Ariño, Ines, Domínguez-Muñoz, Juan Enrique, Aisa, Angeles Perez, Domínguez, Jose Luis, Almela, Pedro, Gomez-Camarero, Judith, Millastre, Judith, Martin-Noguerol, Elisa, Gravina, Antonietta G., Miranda, Agnese, Federico, Alessandro, Bermejo, Miguel Fernandez, Angueira, Teresa, Barceló, Luis Ferrer, Moreno, Nuria Fernandez, Martorano, Marco, Marin, Alicia C, and McNicholl, Adrian G.

Published
2014
Full Text
View/download PDF

38. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).

Author

Martínez-Domínguez SJ, Nyssen OP, Lanas Á, Alfaro E, Jonaitis L, Mahmudov U, Voynovan I, Gülüstan B, Rodrigo L, Fiorini G, Perez-Aisa Á, Tejedor-Tejada J, Tepes B, Vologzanina L, Mammadov E, Lerang F, Oğlu QFV, Bakulina NV, Abdulkhakov R, Tatiana I, Butler TJ, Sarsenbaeva AS, Bumane R, Lucendo AJ, Romano M, Bujanda L, Abdulkhakov SR, Zaytsev O, Pabón-Carrasco M, Keco-Huerga A, Denkovski M, Huguet JM, Perona M, Núñez Ó, Pavoni M, Fadieienko G, Alekseenko S, Smith SM, Hernández L, Kupcinskas J, Bordin DS, Leja M, Gasbarrini A, Gridnyev O, Cano-Català A, Parra P, Moreira L, Mégraud F, O'Morain C, and Gisbert JP

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Drug Therapy, Combination, Europe, Prospective Studies, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Helicobacter Infections drug therapy, Helicobacter pylori drug effects
Abstract

Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori investigation on prescriptions, effectiveness, compliance, and tolerance., Methods: International, prospective, non-interventional registry of the management of H. pylori infection by European gastroenterologists (Hp-EuReg). Treatment-näive patients registered from 2013 to 2023 at e-CRF AEG-REDCap were analyzed. The effectiveness was assessed by modified intention-to-treat analysis., Results: Overall, 53,636 treatment-naïve cases from 34 countries were included. Most frequent indications were: dyspepsia with normal endoscopy (49%), non-investigated dyspepsia (20%), duodenal ulcer (11%), gastric ulcer (7.7%), and gastroesophageal reflux disease (GERD) (2.6%). Therapy effectiveness varied by indication: duodenal ulcer (91%), gastric ulcer (90%), preneoplastic lesions (90%), dyspepsia with normal endoscopy (89%), GERD (88%), and non-investigated dyspepsia (87%). Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies achieved 90% effectiveness in all indications except GERD. Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole reached 90% cure rates except in patients with non-investigated dyspepsia; whereas sequential clarithromycin-amoxicillin-tinidazole/metronidazole proved optimal (≥90%) in patients with gastric ulcer only. Adverse events were higher in patients treated for dyspepsia with normal endoscopy and duodenal ulcer compared with the remaining indications (23% and 28%, p < 0.001). Therapeutic compliance was higher in patients with duodenal ulcer and preneoplastic lesions (98% and 99%, p < 0.001)., Conclusion: In Europe, patients with gastric or duodenal ulcers and preneoplastic lesions showed higher H. pylori treatment effectiveness. Bismuth and non-bismuth quadruple therapies achieved optimal results in almost all indications., Trial Registration: ClinicalTrials.gov identifier: NCT02328131., (© 2024 The Author(s). Helicobacter published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

39. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.

Author

Pabón-Carrasco M, Keco-Huerga A, Castro-Fernández M, Saracino IM, Fiorini G, Vaira D, Pérez-Aísa Á, Tepes B, Jonaitis L, Voynovan I, Lucendo AJ, Lanas Á, Martínez-Domínguez SJ, Almajano EA, Rodrigo L, Vologzanina L, Brglez Jurecic N, Denkovski M, Bujanda L, Abdulkhakov RA, Huguet JM, Fernández-Salazar L, Alcaide N, Velayos B, Silkanovna Sarsenbaeva A, Zaytsev O, Ilchishina T, Barrio J, Bakulin I, Perona M, Alekseenko S, Romano M, Gravina AG, Núñez Ó, Gómez Rodríguez BJ, Ledro-Cano D, Pellicano R, Bogomolov P, Domínguez-Cajal M, Almela P, Gomez-Camarero J, Bordin DS, Gasbarrini A, Kupčinskas J, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, and Gisbert JP

Subjects
Adult, Humans, Proton Pump Inhibitors therapeutic use, Metronidazole, Clarithromycin therapeutic use, Levofloxacin therapeutic use, Bismuth, Prospective Studies, Drug Therapy, Combination, Anti-Bacterial Agents therapeutic use, Amoxicillin therapeutic use, Tetracycline, Registries, Helicobacter pylori, Helicobacter Infections drug therapy
Abstract

Background: Management of Helicobacter pylori (H. pylori) infection requires co-treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication., Aim: To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the 'European Registry on Helicobacter pylori management' (Hp-EuReg)., Methods: Hp-EuReg is a multicentre, prospective, non-interventionist, international registry on the routine clinical practice of H. pylori management by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022., Results: Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first-line-modified intention-to-treat effectiveness was achieved with the following treatments: (1) 14-day therapies with clarithromycin-amoxicillin-bismuth and metronidazole-tetracycline-bismuth, both independently of the PPI dose prescribed; (2) All 10-day (except 10-day standard triple therapy) and 14-day therapies with high-dose PPIs; and (3) 10-day quadruple therapies with clarithromycin-amoxicillin-bismuth, metronidazole-tetracycline-bismuth, and clarithromycin-amoxicillin-metronidazole (sequential), all with standard-dose PPIs. In first-line treatment, optimal effectiveness was obtained with high-dose PPIs in all 14-day treatments, in 10- and 14-day bismuth quadruple therapies and in 10-day sequential with standard-dose PPIs. Optimal second-line effectiveness was achieved with (1) metronidazole-tetracycline-bismuth quadruple therapy for 14- and 10 days with standard and high-dose PPIs, respectively; and (2) levofloxacin-amoxicillin triple therapy for 14 days with high-dose PPIs. None of the 7-day therapies in both treatment lines achieved optimal effectiveness., Conclusions: We recommend, in first-line treatment, the use of high-dose PPIs in 14-day triple therapy and in 10-or 14-day quadruple concomitant therapy in first-line treatment, while standard-dose PPIs would be sufficient in 10-day bismuth quadruple therapies. On the other hand, in second-line treatment, high-dose PPIs would be more beneficial in 14-day triple therapy with levofloxacin and amoxicillin or in 10-day bismuth quadruple therapy either as a three-in-one single capsule or in the traditional scheme., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.)

Published
2024
Full Text
View/download PDF

40. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.

Author

Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, and Gisbert JP

Subjects
Adolescent, Adult, Anti-Bacterial Agents adverse effects, Bismuth adverse effects, Capsules, Drug Combinations, Drug Resistance, Bacterial, Europe, Female, Humans, Intention to Treat Analysis, Male, Medication Adherence, Metronidazole administration & dosage, Metronidazole adverse effects, Middle Aged, Proton Pump Inhibitors adverse effects, Registries, Tetracycline administration & dosage, Tetracycline adverse effects, Young Adult, Anti-Bacterial Agents administration & dosage, Bismuth administration & dosage, Gastrointestinal Diseases drug therapy, Gastrointestinal Diseases microbiology, Helicobacter Infections drug therapy, Helicobacter pylori, Proton Pump Inhibitors administration & dosage
Abstract

Background: There has been resurgence in the use of bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) for treating Helicobacter pylori infection thanks to a three-in-one single-capsule formulation., Objective: To evaluate the effectiveness and safety of the single-capsule bismuth quadruple therapy., Methods: Data were collected in a multicentre, prospective registry of the clinical practice of gastroenterologists on the management of H. pylori infection, where patients were registered at the Asociación Española de Gastroenterologia REDCap database on an electronic case report form until January 2020. Effectiveness by modified intention-to-treat and per-protocol as well as multivariable analysis were performed. Independent factors evaluated were: age, gender, indication, compliance, proton pump inhibitor dose and treatment line., Results: Finally, 2100 patients were prescribed single-capsule bismuth quadruple therapy following the technical sheet (i.e., three capsules every 6 h for 10 days). The majority of these patients were naive (64%), with an average age of 50 years, 64% women and 16% with peptic ulcer. An overall modified intention-to-treat effectiveness of 92% was achieved. Eradication was over 90% in first-line treatment (95% modified intention-to-treat, n = 1166), and this was maintained as a rescue therapy, both in second (89% modified intention-to-treat, n = 375) and subsequent lines of therapy (third to sixth line: 92% modified intention-to-treat, n = 236). Compliance was the factor most closely associated with treatment effectiveness. Adverse events were generally mild to moderate, and 3% of patients reported a severe adverse event, leading to discontinuation of treatment in 1.7% of cases., Conclusions: Single-capsule bismuth quadruple therapy achieved H. pylori eradication in approximately 90% of patients in real-world clinical practice, both as a first-line and rescue treatment, with good compliance and a favourable safety profile., (© 2020 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.)

Published
2021
Full Text
View/download PDF

41. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).

Author

Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, and Gisbert JP

Subjects
Anti-Bacterial Agents therapeutic use, Bismuth therapeutic use, Clarithromycin therapeutic use, Helicobacter pylori drug effects, Humans, Levofloxacin therapeutic use, Metronidazole therapeutic use, Penicillins therapeutic use, Prospective Studies, Proton Pump Inhibitors therapeutic use, Registries statistics & numerical data, Tetracycline therapeutic use, Drug Hypersensitivity, Drug Therapy, Combination, Helicobacter Infections drug therapy, Penicillins adverse effects
Abstract

Background: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended., Aim: To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg)., Methods: A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019., Results: One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera ® ; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases., Conclusion: In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results., (© 2020 John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results